636 reports of this reaction
1.3% of all MINOCYCLINE HYDROCHLORIDE reports
#16 most reported adverse reaction
C REACTIVE PROTEIN INCREASED is the #16 most commonly reported adverse reaction for MINOCYCLINE HYDROCHLORIDE, manufactured by Melinta Therapeutics, LLC. There are 636 FDA adverse event reports linking MINOCYCLINE HYDROCHLORIDE to C REACTIVE PROTEIN INCREASED. This represents approximately 1.3% of all 49,345 adverse event reports for this drug.
Patients taking MINOCYCLINE HYDROCHLORIDE who experience c reactive protein increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
C REACTIVE PROTEIN INCREASED is a less commonly reported adverse event for MINOCYCLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to c reactive protein increased, the following adverse reactions have been reported for MINOCYCLINE HYDROCHLORIDE:
The following drugs have also been linked to c reactive protein increased in FDA adverse event reports:
C REACTIVE PROTEIN INCREASED has been reported as an adverse event in 636 FDA reports for MINOCYCLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
C REACTIVE PROTEIN INCREASED accounts for approximately 1.3% of all adverse event reports for MINOCYCLINE HYDROCHLORIDE, making it a notable side effect.
If you experience c reactive protein increased while taking MINOCYCLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.